Abiraterone acetate for castration resistant prostate cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69(12):4937-40
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
   PubMed Web of Science ®Google Scholar
• Small EJ, Halabi S, Dawson NA, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a Phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33
   PubMed Web of Science ®Google Scholar
• Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132-8, discussion 8-9
   PubMed Web of Science ®Google Scholar
• Chodak GW. Maximum androgen blockade: a clinical update. Rev Urol 2005;7(Suppl 5):S13-7
   PubMedGoogle Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45
   PubMed Web of Science ®Google Scholar
• So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23(1):1-9
   PubMed Web of Science ®Google Scholar
• Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;100(5):671-5
   PubMed Web of Science ®Google Scholar
• Forti G, Salerno R, Moneti G, Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab 1989;68(2):461-8
   PubMed Web of Science ®Google Scholar
• Geller J, Liu J, Albert J, Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf) 1987;26(2):155-61
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-54
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-8
   PubMed Web of Science ®Google Scholar
• Culig Z, Stober J, Gast A, Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996;20(1):68-75
   PubMedGoogle Scholar
• Tan J, Sharief Y, Hamil KG, Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11(4):450-9
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, Ford OH III, The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440-8
   PubMed Web of Science ®Google Scholar
• Page ST, Lin DW, Mostaghel EA, Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91(10):3850-6
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Belanger A, Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187(2):169-96
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lehman ML, Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2010;70(3):239-51
   Google Scholar
• Stanbrough M, Bubley GJ, Ross K, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217-27
   PubMed Web of Science ®Google Scholar
• Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008;295(1-2):115-20
   PubMed Web of Science ®Google Scholar
• Locke JA, Wasan KM, Nelson CC, Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). Prostate 2008;68(1):20-33
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lubik AA, Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-15
   PubMed Web of Science ®Google Scholar
• Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8(4):449-57
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5(11):610-20
   PubMedGoogle Scholar
• Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157(4):1204-7
   PubMed Web of Science ®Google Scholar
• Bubley GJ, Carducci M, Dahut W, Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-7
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Halabi S, Ou SS, Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 2007;13(7):2030-7
   PubMed Web of Science ®Google Scholar
• Savarese DM, Halabi S, Hars V, Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19(9):2509-16
   PubMed Web of Science ®Google Scholar
• Handratta VD, Vasaitis TS, Njar VC, Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48(8):2972-84
   PubMed Web of Science ®Google Scholar
• Millennium Pharmaceuticals I. Investigator's Brochure TAK-700, 10 December 2008, Edition 5
   Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
   PubMed Web of Science ®Google Scholar
• Barrie SE, Potter GA, Goddard PM, Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50(5-6):267-73
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71
   PubMed Web of Science ®Google Scholar
• Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38(13):2463-71
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Judson I, Dowsett M, Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-25
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Hance J, Darzi A. The development of a surgical education program. Cir Esp 2005;77(1):1-2
   PubMedGoogle Scholar
• Attard G, Swennenhuis JF, Olmos D, Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69(7):2912-8
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Lin AM, Huey V, Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17 alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer. 2008 ASCO Genitourinary Cancers Symposium Abstract No 157
   Google Scholar
• Ryan CJ, Fong L, Rosenberg JE, Phase I clinical trial of the CYP 17 inhibitor abiraterone Acetate (CB7630), demonstrating clinical activity in castration-resistant prostate cancer patients with prior ketoconazole therapy. J Clin Oncol 2009. In Press
   Web of Science ®Google Scholar
• Danila D, Rathkopf D, Fleisher M, Preliminary Phase II results of abiraterone acetate in patients with castration resistant metastatic prostate cancer after failure of docetaxelbased chemotherapy. Proceedings of the 2008 Genitourinary Cancers Symposium Abstract No 3 2008
   Google Scholar
• Reid AH, Attard G, Danila D, A multicenter Phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 2009;27:15S: abstract 5047
   Web of Science ®Google Scholar
• Ryan C, Efstathiou E, Smith M, Abiraterone acetate plus prednisone in chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: results of a multicenter Phase II study. 2009 Genitourinary Cancers Symposium 2009; abstract 159
   Google Scholar
• Ryan C. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009;27:15S: abstract 5046
   Google Scholar
• Attard G, Reid AH, A'Hern R, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
   PubMed Web of Science ®Google Scholar